VistaGen Therapeutics, Inc. (VTGN): Price and Financial Metrics
VTGN Stock Summary
- VTGN's price/sales ratio is 472.61; that's higher than the P/S ratio of 98.45% of US stocks.
- As for revenue growth, note that VTGN's revenue has grown 93.89% over the past 12 months; that beats the revenue growth of 94.44% of US companies in our set.
- In terms of volatility of its share price, VTGN is more volatile than 94.28% of stocks we're observing.
- Stocks with similar financial metrics, market capitalization, and price volatility to VistaGen Therapeutics Inc are CAPR, FREQ, HRTX, RESN, and BCDA.
- VTGN's SEC filings can be seen here. And to visit VistaGen Therapeutics Inc's official web site, go to www.vistagen.com.
VTGN Stock Price Chart Interactive Chart >
VTGN Price/Volume Stats
| Current price | $2.16 | 52-week high | $3.18 |
| Prev. close | $2.19 | 52-week low | $0.35 |
| Day low | $2.08 | Volume | 737,100 |
| Day high | $2.20 | Avg. volume | 3,545,751 |
| 50-day MA | $2.21 | Dividend yield | N/A |
| 200-day MA | $1.25 | Market Cap | 309.61M |
VistaGen Therapeutics, Inc. (VTGN) Company Bio
VistaGen Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The Company develops products for patients with diseases and disorders involving the central nervous system. VistaGen Therapeutics serves customers in the United States.
Latest VTGN News From Around the Web
Below are the latest news stories about VistaGen Therapeutics Inc that investors may wish to consider to help them evaluate VTGN as an investment opportunity.
VISTAGEN THERAPEUTIC (VSTA) Q4 2020 Earnings Call TranscriptWith me on the call today, we have Mario Ghio, Vasta's CEO; Clovis Poggetti, our CFO; and Guilherme Melega, Vasta's COO. During today's presentation, our executives will make forward-looking statements. |
VistaGen Therapeutics files for $250M mixed shelfVistaGen Therapeutics (VTGN) has filed a prospectus for a mixed shelf offering of up to $250M.The filing does not necessarily indicate that a sale has begun, or will occur in the future.Shares up 3.5% after-hours. Yesterday's close was $2.35.... |
VistaGen Therapeutics to Participate in Upcoming Investor Conferences in MarchSOUTH SAN FRANCISCO, Calif., March 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that Shawn Singh, VistaGen’s Chief Executive Officer, will participate in the following investor conferences in March: Maxim Group and M-Vest’s Inaugural Emerging Growth Virtual ConferenceDates:March 17th – 19thFormat:Corporate Presentation & One-on-One Fireside Chat Date:Friday, March 19th at 1:00 p.m. ETFormat:Fireside Chat with Jason McCarthy, Research AnalystWebsite:To attend the virtual conference, register here https://www.m-vest.co... |
The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data ReadoutsHere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Feb. 22) Acceleron Pharma Inc (NASDAQ: XLRN ) Akari Therapeutics PLC (NASDAQ: AKTX ) Annexon Inc (NASDAQ: ANNX ) Applied Molecular Transport Inc. (NASDAQ: AMTI ) AxoGen, Inc (NASDAQ: AXGN ) Burning Rock Biotech Ltd (NASDAQ: BNR ) Celcuity Inc (NASDAQ: CELC ) (announced a $20 million common stock offering) Celldex Therapeutics, Inc. (NASDAQ: CLDX ) Cerecor Inc (NASDAQ: CERC ) Citius Pharmaceuticals Inc (NASDAQ: CTXR ) DermTech Inc (NASDAQ: DMTK ) Gemini Therapeutics Inc (NASDAQ: GMTX ) Intra-Cellular Therapies Inc (NASDAQ: ITCI ) (announced NDA submissions for two indications for Caplyta - as monotherapy and as adjunctive therapy with lithium or valpro... |
Why VistaGen Therapeutics Stock Is Soaring TodayThe big jump came after Jefferies analyst Andrew Tsai initiated coverage on the stock with a buy recommendation. Tsai also set a one-year price target of $6, nearly three times the price of VistaGen's shares at the market close on Wednesday. In this case, Tsai really likes the potential for VistaGen's lead pipeline candidate PH94B. |
VTGN Price Returns
| 1-mo | -8.09% |
| 3-mo | -6.90% |
| 6-mo | 182.72% |
| 1-year | N/A |
| 3-year | 89.47% |
| 5-year | -72.97% |
| YTD | 11.34% |
| 2020 | 181.28% |
| 2019 | -54.02% |
| 2018 | 35.14% |
| 2017 | -70.24% |
| 2016 | -62.09% |
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Loading social stream, please wait...